公开(公告)号：US20230203023A1

公开(公告)日：2023-06-29

申请号：US17927502

申请日：2021-05-26

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Meng Jiang ,  Beibei Chen ,  Xudong Wei ,  Wenge Zhong

IPC: C07D405/14 ,  C07C55/22

CPC classification number: C07D405/14 ,  C07C55/22 ,  C07B2200/13

Abstract: Various salt forms of Compound I and Compound II represented by the following structural formulae, and their corresponding pharmaceutical compositions, are disclosed. (I), (II) Particular single crystalline forms of 1:1 Compound I tris salt, 1:1 Compound II tris salt, and 1:1 Compound II citrate salt are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.